Physician profile
Hillary E Griffin
NPI 1144521782
$12,608.09
in general payments reported to CMS, 2019-2025
42 companies · $5,569 in 2025
The $5,569 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $578 · 2023: $2,311 · 2024: $3,541 · 2025: $5,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,970 · Consulting Fee: $2,700 · Education: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,969.79 |
| Consulting Fee | $2,700.00 |
| Education | $751.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,091.42 | 2021-2025 | |
| Janssen Biotech, INC. | $1,459.56 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,293.16 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $697.72 | 2023-2025 | |
| Ucb, INC. | $649.32 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $618.23 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $505.44 | 2024-2025 | Nemluvio, Aklief |
| Amgen INC. | $457.19 | 2023-2025 | Otezla, Enbrel, Otezla |
| Lilly USA, LLC | $433.68 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $372.67 | 2023-2025 | Dupixent, Libtayo |
| Ironshore Pharmaceuticals INC. | $371.49 | 2021-2023 | Jornay Pm |
| Leo Pharma INC. | $276.41 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $233.83 | 2023-2024 | Ilumya, Winlevi, Absorica Ld |
| Tris Pharma INC | $223.52 | 2021-2022 | |
| Genzyme Corporation | $218.62 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $208.47 | 2024-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $184.99 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.17 | 2023-2025 | Spevigo, Cyltezo |
| Dermavant Sciences, INC. | $147.49 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $123.60 | 2024-2025 | Zoryve |
| Adlon Therapeutics L.P. | $93.84 | 2021 | |
| Corium, LLC | $88.31 | 2022-2023 | Azstarys |
| Kaleo, INC. | $74.37 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $65.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.94 | 2021-2022 | |
| Neurelis, INC. | $55.99 | 2022-2023 | Valtoco |
| Organon LLC | $52.25 | 2025 | Vtama |
| Cranial Technologies, INC | $49.00 | 2021-2023 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $43.07 | 2021 | |
| Fresenius Kabi USA, LLC | $42.01 | 2023 | Idacio |
| Sandoz INC. | $37.82 | 2023-2024 | Hyrimoz |
| Aimmune Therapeutics, INC. | $30.41 | 2022 | |
| Sanofi Pasteur INC. | $26.10 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $19.50 | 2024 | Ycanth |
| Botanix Sb INC | $19.32 | 2025 | Sofdra |
| Almirall LLC | $18.95 | 2024 | Klisyri |
| Organogenesis INC. | $18.06 | 2023 | Puraply |
| Supernus Pharmaceuticals, INC. | $16.30 | 2022 | |
| Seqirus USA INC | $15.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.68 | 2021 | |
| Lnhc, INC | $13.62 | 2025 | Zelsuvmi |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.